研究单位：[1]Daiichi Sankyo[2]China-Japan Friendship Hospital,Beijing,China,100029[3]Peking University First Hospital,Beijing,China,100034[4]Peking University Shougang Hospital,Beijing,China,100144[5]Peking University Third Hospital,Beijing,China,100191[6]Sichuan Cancer Hospital,Chengdu,China,610041[7]Sichuan Provincial People's Hospital,Chengdu,China,610072[8]Chongqing University Cancer Hospital,Chongqing,China,400030[9]The Southwest Hospital of AMU,Chongqing,China,400038[10]Affiliated Zhongshan Hospital of Dalian University,Dalian,China,116001[11]The First People's Hospital of Foshan,Foshan,China,528000[12]Fujian Cancer Hospital,Fuzhou,China,350000[13]Sun Yat-sen University Cancer Center,Guangzhou,China,510060[14]The First Affiliated Hospital，Sun Yat-sen University,Guangzhou,China,510080[15]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,China,510120[16]Guangdong Women and Children Hospital,Guangzhou,China,511400[17]Hainan Cancer Hospital,Haikou,China,570311[18]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,China,310009[19]Zhejiang Cancer Hospital,Hangzhou,China,310022[20]Zhejiang Cancer Hospital,Hangzhou,China,325088[21]Harbin Medical University Cancer Hospital,Harbin,China,150081[22]The First Affiliated Hospital of Anhui Medical University,Hefei,China,230022[23]Anhui Provincial Cancer Hospital,Hefei,China,230031[24]Jiamusi Cancer Hospital,Jiamusi,China,154007[25]Yunnan cancer hospital,Kunming,China,650118[26]Lanzhou University First Hospital,Lanzhou,China,730030[27]The First Affiliated Hospital of Henan University of Science & Technology,Luoyang,China,450052[28]Jiangxi Cancer Hospital,Nanchang,China,330000[29]Nanchang Third Hospital,Nanchang,China,330000[30]Nanjing Drum Tower Hospital,Nanjing,China,210008[31]Jiangsu Province Hospital,Nanjing,China,210029[32]The Peoples of Guangxi Zhuang Autonomous Region,Nanning,China,541000[33]Affiliated Hospital Of Nantong University,Nantong,China,226001[34]Ningbo No.2 Hospital,Ningbo,China,315010[35]Fudan University Shanghai Cancer Center,Shanghai,China,200000[36]Ruijin Hospital, Shanghai Jiaotong University School Of Medicine,Shanghai,China,200025[37]Tenth People's Hospital of Tongji University,Shanghai,China,200072[38]Shanghai General Hospital,Shanghai,China,200080[39]Changhai Hospital,Shanghai,China,200433[40]Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center,Shenzhen,China,518116[41]Shanxi Provincial Cancer Hospital,Taiyuan,China,030000[42]Affiliated Cancer Hospital of Xinjiang Medical University,Wulumuqi,China,830011[43]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,China,710061[44]The First Affilital of Xiamen University,Xiamen,China,361003[45]Yancheng No.1 People's Hospital,Yancheng,China,224001[46]General Hospital of Ningxia Medical University,Yinchuan,China,750003[47]Henan Cancer Hospital,Zengzhou,China,450003[48]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,China,100142[49]Henan Provincial People's Hospital,Zhengzhou,China,463599[50]The Fifth Affiliated Hospital，Sun Yat-sen University,Zhuhai,China,519000
This multi-center observational prospective study will collect real-world clinical and patient-reported outcome data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens or patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+, ISH-) breast cancer who have received at least a prior systemic therapy in the metastatic setting, or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
